The contribution of the donor vascularised hand and face allograft in transplant rejection: An immunological perspective

Amin, Kavit R.; Fildes, James E.

doi:10.1016/j.trim.2024.102035

Cited by 1 publication

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Solid organ transplantation faces distinct challenges related to organ compatibility, ischemia-reperfusion injury, and the imperative for lifelong immunosuppression [32][33][34]. Similarly, VCA transplantation introduces additional complexities due to the unique requisites of VCA organs, such as the face, hands, or uterus, and the inherent risk of rejection [35][36][37]. Addressing these challenges requires efforts to introduce and develop novel therapeutic approaches capable of enhancing graft survival, promoting tissue regeneration, and improving long-term outcomes across the diverse spectrum of transplantation and regenerative medicine.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Engraftment and Safety of Human Umbilical Di-Chimeric Cell (HUDC) Therapy after Systemic Intraosseous Administration in an Experimental Model

Siemionow,

Chambily,

Brodowska

2024

Biomedicines

View full text Add to dashboard Cite

Cell-based therapies hold promise for novel therapeutic strategies in regenerative medicine. We previously characterized in vitro human umbilical di-chimeric cells (HUDCs) created via the ex vivo fusion of human umbilical cord blood (UCB) cells derived from two unrelated donors. In this in vivo study, we assessed HUDC safety and biodistribution in the NOD SCID mouse model at 90 days following the systemic intraosseous administration of HUDCs. Twelve NOD SCID mice (n = 6/group) received intraosseous injection of donor UCB cells (3.0 × 106) in Group 1, or HUDCs (3.0 × 106) in Group 2, without immunosuppression. Flow cytometry assessed hematopoietic cell surface markers in peripheral blood and the presence of HLA-ABC class I antigens in lymphoid and non-lymphoid organs. HUDC safety was assessed by weekly evaluations, magnetic resonance imaging (MRI), and at autopsy for tumorigenicity. At 90 days after intraosseous cell administration, the comparable expression of HLA-ABC class I antigens in selected organs was found in UCB control and HUDC therapy groups. MRI and autopsy confirmed safety by no signs of tumor growth. This study confirmed HUDC biodistribution to selected lymphoid organs following intraosseous administration, without immunosuppression. These data introduce HUDCs as a novel promising approach for immunomodulation in transplantation.

show abstract